Table 1—

Demographic and clinical characteristics at study entry

Inhaled insulinSubcutaneous insulin
n149149
Sex (M/F)99/5099/50
Age (years)58.7 ± 9.5 (35–80)56.2 ± 11.1 (23–78)
Duration of diabetes (years)13.8 (0.4–59.0)13.2 (0.9–43.4)
Weight (kg)
    Men93.7 ± 13.4 (63–126)91.5 ± 13.5 (65–123)
    Women82.3 ± 12.8 (59–115)83.4 ± 12.4 (59–123)
    Mean89.9 ± 14.288.8 ± 13.7
BMI (kg/m2)
    Men29.9 ± 3.8 (21–38)29.5 ± 3.6 (21–38)
    Women31.7 ± 5.1 (22–51)31.1 ± 3.9 (22–38)
HbA1c (%)8.48 ± 1.24 (6.5–11.9)8.47 ± 1.20 (5.8–11.6)
C-peptide (pmol/ml)0.61 ± 0.41 (0.17–3.23)0.58 ± 0.37 (0.07–2.81)
Short-acting insulin (units)23.17 (1.0–92.0)23.79 (4.0–110.0)
    n105107
Long/intermediate-acting insulin (units)41.27 (5.0–115.0)41.66 (8.0–144.0)
    n112117
Premixed short/intermediate-acting insulin (units)61.79 (14.0–140.0)49.03 (11.0–90.0)
    n3936
  • Data are means ± SD.